Louise R. Rodino‐Klapac
Biochemistry, Genetics and Molecular Biology · The Ohio State University
Publications
172
Citations
10,154
Est. group size
~4
Recurring co-author estimate
Active years
27
Publishing since 2000
Louise R. Rodino-Klapac's research focuses on developing gene therapies for muscular dystrophies, particularly Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophy (LGMD), using engineered viruses (AAV vectors) to deliver corrective genes to muscle tissue. Her recent work includes clinical trial results, safety and immune-response studies, and pharmacological characterization of these gene therapy candidates, most notably delandistrogene moxeparvovec and bidridistrogene xeboparvovec.
Publication output has declined somewhat over the past decade, from around 20 papers in 2017 to a more modest and fluctuating pace averaging about 8 per year over the last five years, with a notable spike in 2023.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Two-Year Outcomes Following Delandistrogene Moxeparvovec Treatment in Ambulatory Patients with Duchenne Muscular Dystrophy: Phase 3 EMBARK Trial
Neurology and Therapy · 2026
- Limb-Girdle Muscular Dystrophy Scientific Workshop
Neurology Clinical Practice · 2025
- Immunologic investigations into transgene directed immune-mediated myositis following delandistrogene moxeparvovec gene therapy
Scientific Reports · 2025
- Quantitative Muscle Magnetic Resonance Outcomes in Patients With Duchenne Muscular Dystrophy
JAMA Neurology · 2025
- 80PDelandistrogene moxeparvovec in Duchenne muscular dystrophy: long-term EMBARK 2-year functional outcomes, safety, and micro-dystrophin expression
Neuromuscular Disorders · 2025
- Long-Term Functional Outcomes, Safety, and Micro-Dystrophin Expression Following Delandistrogene Moxeparvovec Treatment in DMD: EMBARK 2-Year Results
Neuropediatrics · 2025
- Pharmacokinetic and Pharmacodynamic Evaluation of Bidridistrogene Xeboparvovec in an Aged Murine Model of Limb-Girdle Muscular Dystrophy Type 2E/R4
Human Gene Therapy · 2025
- AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial
Nature Medicine · 2024
- Use of plasmapheresis to lower anti-AAV antibodies in nonhuman primates with pre-existing immunity to AAVrh74
Molecular Therapy — Methods & Clinical Development · 2024
- Gene therapy with bidridistrogene xeboparvovec for limb-girdle muscular dystrophy type 2E/R4: phase 1/2 trial results
Nature Medicine · 2024
- Long-Term Survival and Myocardial Function Following Systemic Delivery of Delandistrogene Moxeparvovec in DMD <sup>MDX</sup> Rats
Human Gene Therapy · 2024
- Characterization of Nonclinical Drug Metabolism and Pharmacokinetic Properties of Phosphorodiamidate Morpholino Oligonucleotides, a Novel Drug Class for Duchenne Muscular Dystrophy
Drug Metabolism and Disposition · 2024
- 423P Safety and efficacy of delandistrogene moxeparvovec versus placebo in Duchenne muscular dystrophy: phase 3 EMBARK primary results
Neuromuscular Disorders · 2024
- Safety and Efficacy of Delandistrogene Moxeparvovec versus Placebo in Duchenne Muscular Dystrophy (EMBARK): Pivotal Phase 3 Primary Results
Neuropediatrics · 2024
- Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy
Frontiers in Cell and Developmental Biology · 2023
- Neuromuscular Disorders×22
- Neurology×21
- Molecular Therapy×8
- Human Gene Therapy×7
- Molecular Therapy — Methods & Clinical Development×6
- Afrooz Rashnonejad
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Jerry R. Mendell
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Renzhi Han
Biochemistry, Genetics and Molecular Biology · Indiana University
- Kevin M. Flanigan
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Paul T. Martin
Biochemistry, Genetics and Molecular Biology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile